Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hoping they provide an update soon

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Jun 07, 2021 6:18pm

145 Views

Post# 33345070

RE:RE:Hoping they provide an update soon

The company should be working overtime to prevent a bleed. They don’t deserve a vacation lol.
this drug is a slam dunk and yet management can’t seem to hit the mark with a beat in class drug. Dan is a joke.

Actuarial wrote: May - Oct is the traditional summer vacation period. So, I would not expect much news. Ph3 will come, Nasdaq will come, partnership deal will come, but it would not be an immediate thing. Let's take a break and enjoy the summer. When we come back, ATE will surprise you. GLTA longs!

markymark11 wrote: Would love to hear about their progress on the following items:

remaining ph3-enabling animal studies

tablet production and CMC

enhanced AME study

Of course, a surprise partnership announcement would be most welcome as well.